B-cell Lymphoma Recurrent Clinical Trials

4 recruiting

B-cell Lymphoma Recurrent Trials at a Glance

7 actively recruiting trials for b-cell lymphoma recurrent are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Shanghai, El Palmar, and Hangzhou. Lead sponsors running b-cell lymphoma recurrent studies include Jennifer Crombie, MD, Nelson Hamerschlak, and Instituto de Investigación Biomédica de Salamanca.

Browse b-cell lymphoma recurrent trials by phase

Treatments under study

About B-cell Lymphoma Recurrent Clinical Trials

Looking for clinical trials for B-cell Lymphoma Recurrent? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new B-cell Lymphoma Recurrent trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about B-cell Lymphoma Recurrent clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 1Phase 2

Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma

CNS MetastasesB-cell Lymphoma RecurrentB-cell Lymphoma Refractory
Samsung Medical Center37 enrolled2 locationsNCT06552559
Recruiting
Phase 1Phase 2

Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology

B-cell Lymphoma RecurrentRefractory B-Cell Lymphoma
Instituto de Investigación Biomédica de Salamanca27 enrolled8 locationsNCT06378190
Recruiting
Phase 2

Pembro Plus CAR T-cell Therapy in R/R in PMBCL

Primary Mediastinal Large B Cell LymphomaPrimary Mediastinal Large B-cell Lymphoma (PMBCL)Primary Mediastinal Large B-Cell Lymphoma Refractory+3 more
Jennifer Crombie, MD35 enrolled2 locationsNCT05934448
Recruiting
Phase 1

Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies

Acute Lymphoblastic Leukemia, in RelapseAcute Lymphoblastic Leukemia RefractoryB-cell Lymphoma Recurrent+3 more
Nelson Hamerschlak30 enrolled1 locationNCT05705570
Recruiting
Phase 2

A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL

Diffuse Large B-cell Lymphoma RecurrentDiffuse Large B Cell Lymphoma Refractory
Zhejiang Cancer Hospital41 enrolled1 locationNCT06086197
Recruiting
Phase 1

CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL

Acute Lymphoblastic Leukemia, in RelapseB-cell Lymphoma RecurrentB-cell Lymphoma Refractory+1 more
Rong Tao48 enrolled2 locationsNCT06445803
Recruiting
Phase 2

Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL

Diffuse Large B-cell Lymphoma RecurrentDiffuse Large B Cell Lymphoma Refractory
RenJi Hospital20 enrolled1 locationNCT06033820